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ABSTRACT 
Objective: To determine the period prevalence of IBS and comorbid depression among 
individuals with irritable bowel syndrome (IBS) in multi-state Medicaid population, and to 
assess the impact of comorbid depression on healthcare utilization and costs among individuals 
with IBS enrolled in Fee-for-Service Medicaid program. 
 
Methods: A retrospective cohort study was conducted using 2006-2008 Medicaid Analytic 
Extract files for 39 states.  Beneficiaries with IBS were identified based on any medical claims 
for the disease.  Beneficiaries with one or more medical claims for depression during the study 
period were considered to have had comorbid depression.  For each beneficiary, the first claim 
for IBS in 2007 was considered as the index date.  12-month post index date all-cause and IBS-
related healthcare utilization and costs were computed for each of the four medical service 
components – inpatient, outpatient, emergency room, and prescription drug.  Generalized linear 
models were used to assess the impact of comorbid depression on healthcare utilization and 
costs. 
Results: The period prevalence of IBS in the population was 4.4 per 1,000 Medicaid 
beneficiaries.  The period prevalence of comorbid depression among beneficiaries with IBS was 
26.88%.  Beneficiaries with IBS and depression had significantly greater all-cause and IBS-
related inpatient, IBS-related outpatient, all-cause emergency room, all-cause and IBS-related 
prescription drug utilization, and IBS-related outpatient, all-cause and IBS-related emergency 
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room, and all-cause and IBS-related prescription drug costs as compared to those without 
depression. 
Conclusion: Given the impact on healthcare use and costs, there is a need for better screening 
and management of depression in this population.  
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INTRODUCTION 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by 
abdominal pain, bloating, and alternating bowel habits.  Over the past few decades, the criteria 
for IBS diagnosis has changed from being exclusion based to symptom based. The various 
symptom based models that are in place for IBS diagnosis are Manning, Rome I, Rome II, and 
Rome III criteria.  Based on the symptoms of the disease, IBS can be divided into three subtypes 
– IBS constipation-dominant (IBS-C), IBS diarrhea-dominant (IBS-D), and IBS alternating 
between constipation and diarrhea or mixed IBS (IBS-M).
Among all gastrointestinal diseases, IBS has a very high frequency.  At least one in ten 
primary care visits and approximately one-fourth to one-half of gastroenterology referral visits 
can be attributed to IBS (Talley, Zinsmeister, Van Dyke, C. A. R. O. L., & Melton, 1991). In the 
United States (US), IBS prevalence varies based on the criteria used for determining disease and 
the study population.  Prevalence for IBS has been estimated to be as high as 20%, with the 
general range of prevalence report to be 10-15% (Saito, Schoenfeld, & Locke III, 2002).  
Irrespective of the criteria used, the prevalence for IBS also varies by its subtypes (Hungin, 
Whorwell, Tack, & Mearin, 2003; Guilera, Balboa, & Mearin, 2005). The prevalence of IBS-M 
has been reported to be four times that of IBS-C, and three times that of IBS-D (Hungin et al., 
2003).  Prevalence is said to vary by demographic factors including age and gender.  In a study 
conducted by Drossman et al. (1993), IBS prevalence was observed to be higher among 
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individuals aged less than 45 years as compared to those aged 45 years and above.  As per 
gender, the prevalence of IBS has been reported to be 2-3 times as high among females as 
compared to males (Drossman et al., 1993; Hahn, Saunders, & Maier, 1997; Thompson, Heaton, 
Smyth, & Smyth, 2000).    
IBS has a marked impact on healthcare use and costs, driven by the variability of disease 
symptoms and uncertain nature of its diagnosis and treatment.  In their study of healthcare 
burden, Talley et al. (1995) found the healthcare costs among individuals with IBS to be 1.6 
times higher than those without IBS.  Similar results were observed by Levy et al. (2001), who 
also found higher healthcare costs associated with IBS diagnosis.  A systematic review of cost-
of-illness for IBS in the US reported that direct medical cost for each individual with the disease 
ranged from $1,500 to $7,500 approximately with outpatient, inpatient, and pharmacy 
expenditures being the predominant drivers of cost (Nellesen, Yee, Chawla, Lewis, & Carson, 
2013).  Another systematic literature search of studies on the cost of IBS in the UK and US that 
were published between 1991 and 2003 found the cost of disease to vary from around $350 to 
approximately $9,000 annually for each individual afflicted with the disease (Maxion-
Bergemann, Thielecke, Abel, & Bergemann, 2006).  Besides causing considerable health and 
economic burden, IBS also adversely impacts work productivity and increase in work 
absenteeism (Leong et al., 2003).  
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LITERATURE REVIEW 
According to the American Gastroenterological Association, irritable bowel syndrome (IBS) is 
defined as “a combination of chronic or recurrent GI symptoms not explained by structural or 
biochemical abnormalities, which is attributed to the intestines and associated with symptoms of 
pain and disturbed defecation and/or symptoms of bloatedness and distention” (American 
Gastroenterological Association, 1997).  IBS is associated with chronic, recurring abdominal 
pain or unease due to alteration in bowel habit, or both, without any trace of structural anomalies 
to explain these symptoms.  
IBS Diagnosis and Subtypes 
The diagnostic criteria for IBS has changed over the past few decades, from a system which used 
various exclusion criteria to the use of symptom-based models such as Manning criteria, Rome I, 
Rome II, and Rome III.  The Manning criteria, developed in the 1970s, includes questions about 
pain, and whether it is relieved by defecation, increase in frequency of stool at pain initiation, 
looser stools at the origin of pain, explicit abdominal swelling, feeling of unfinished emptying, 
and flow of mucus through rectum (Manning, Thompson, Heaton, & Morris, 1978).  The Rome I 
criteria, incorporated in 1990, embraced the majority of the Manning criteria.  However, ensuing 
factor analysis on the criteria revealed that the first three symptoms, namely relief of pain on 
defecation, incidence of looser stools and increase in frequency of stools with pain, clustered 
well together while the remaining symptoms did not (Heller, & Schuster, 1990; Talley, Boyce, & 
Jones, 1998).  These considerations were taken into account while framing the Rome II criteria, 
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established in 1999, along with recognition that the resultant pain may stem from hard stool as 
well as loose stool (Thompson et al., 1999).  The Rome III criteria framed in 2006, modified the 
Rome II criteria by taking into account the fact that for a person to be identified with IBS, he or 
she must have had feelings of abdominal pain at least 3 days per month in the preceding 3 
months along with two of the three symptoms listed under Rome II (Longstreth et al., 2006).  
Based on the symptoms of the disease, IBS can be divided into three subtypes – IBS 
constipation-dominant (IBS-C), IBS diarrhea-dominant (IBS-D), and IBS alternating between 
constipation and diarrhea (IBS-M).  The Rome III criteria, which is reliant majorly on the 
consistency of stool, identifies IBS-C as cases where patients have hard stools more than 25% of 
the time and loose stools less than 25% of time.  When patients experience loose stools more 
than 25% and hard stools less than 25% of the time then they are classified as IBS-D.  Patients 
that experience both hard and loose stool more than 25% of the time are said to be afflicted with 
IBS-M (Tillisch et al., 2005).   
Prevalence and Incidence of IBS 
Among all the diseases affecting the gastrointestinal tract, IBS is the most frequent.  
Approximately one in ten primary care visits and up to one-half of gastroenterology referral 
visits can be attributed to IBS (Talley et al., 1991).  In the United States (US), IBS prevalence 
varies based on the determination criteria and the study population amongst other factors. 
Prevalence rates for IBS have been reported to vary between 3% and 20%, with most estimates 
reported to be between 10% and 15% (Saito et al., 2002).  This variation in prevalence rates can 
be partly attributed to differences in the threshold criteria for the diagnosis of IBS.  In a 
population-based mail survey conducted by Saito et al. (2000), variation in threshold criteria for 
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IBS diagnosis such as presence of two, three, and four or more Manning symptoms and recurring 
abdominal pain yielded prevalence rates of 17.0, 12.8 and 8.7 per 100, respectively.  
Variation in prevalence of IBS subtypes has been noted based on determination criteria 
(Hungin et al., 2003; Guilera et al., 2005).  When using the Rome criteria for IBS diagnosis 
among individuals residing across eight countries in Europe, Hungin and colleagues (2003) 
found the prevalence of IBS-A to be four times higher than IBS-C and three times higher than 
IBS-D.  In contrast, Talley and colleagues (1995) found similar prevalence of IBS-C, IBS-D, and 
IBS-A (~5%) when using Manning criteria for case ascertainment in a US-based sample.   
Studies have revealed difference in prevalence of IBS among males and females, with 
prevalence reported to be roughly 2-3 times as high in the latter group as compared to the former 
(Drossman et al., 1993; Hahn et al., 1997; Thompson et al., 2000).  Variation in IBS prevalence 
has also been reported.  As per age, studies have found inconsistent results.  Some have reported 
higher prevalence of IBS among adolescents and young adults as compared to older age groups 
(Drossman et al., 1993; Thompson et al., 2000). Others have noted the prevalence of IBS to 
increase with age, with prevalence being 8% for those aged between 65 to 74 years and 12% for 
those older having age greater than 85 years (Talley, O’Keefe, Zinsmeister, & Melton, 1992).  
Unlike prevalence, it is difficult to measure the incidence of IBS considering that the 
symptoms of IBS manifest slowly and that individuals do not always seek care for symptoms 
associated with IBS. A population-based study in the US, based on data from two surveys 
conducted on the same sample one-year apart estimated the incidence of IBS to be around 10% 
(Cremonini, & Talley, 2005).  However, when incidence was determined using physician-based 
diagnosis in the same sample, a substantially lower incidence rate of 196 cases per 100,000 
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person-years was observed (Locke et al., 2004).  In their systematic review of the incidence of 
post-infectious IBS, Thabane and colleagues (2007) estimated an IBS incidence rate of 10% 
among individuals with a history of acute gastrointestinal infection.  
Healthcare Utilization and Costs of IBS 
Driven by the variability of disease symptoms and uncertain nature of its diagnosis and 
treatment, IBS has a marked impact on healthcare use and costs. When examining the medical 
costs of IBS through a self-reported questionnaire, Talley and colleagues (1995) found the 
healthcare costs to be 60% greater for individuals with IBS than a control group of individuals 
without IBS.  A recent study of a commercially insured sample of individuals with IBS-C found 
the incremental all-cause healthcare spending associated with the disease to be ~$4,000 per 
member per year, with almost 80% of the incremental spending attributable to medical services 
(Doshi et al., 2014).  Similar results have been observed in other studies, with higher outpatient 
visits, more frequent inpatient stays, and greater medication prescriptions reported among 
individuals with IBS as compared to those without IBS (Longstreth et al., 2003).  A study 
conducted on the cost of care for individuals with IBS enrolled in a health maintenance 
organization found that the cost incurred towards healthcare for those with IBS was 1.5 times the 
cost incurred for those without IBS. The study noted that barring hospitalization, all other aspects 
of costs were greater for individuals with IBS as compared to those without the disease. The 
study further noted that even though individuals with IBS recorded higher costs for lower GI 
services, only one-third of the total cost difference between those with and without IBS could be 
attributed to services related to lower GI (Levy et al., 2001).  Studies have also revealed that 
annual healthcare visits made for gastrointestinal and non-gastrointestinal issues to be 
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significantly greater for individuals with IBS, as compared to those without IBS (Levy, 
Whitehead, Von Korff, & Feld, 2000; Drossman et al., 1993).   
The utilization of healthcare resources among individuals with IBS is chiefly associated 
with serial diagnostic tests and invasive procedures and operations (American 
Gastroenterological Association, 2001).  In their multivariate analysis on the association between 
IBS and surgical procedures in physician-diagnosed IBS patients, Longstreth and colleagues 
(2004) found cholecystectomy rates to be thrice as great for individuals with IBS as compared to 
those without IBS. Rates for appendectomy and hysterectomy were also twice as high among 
individuals with IBS as compared to those without IBS. Further, back surgery rate were 50% 
higher in IBS group as compared to those without IBS.  When assessing colonoscopy utilization 
in different clinical settings, Lieberman and colleagues (2005) found that almost one in every 
four colonoscopy performed in individuals less than 50 years of age were attributable to IBS.  
Healthcare use and spending among individuals with IBS is not only higher than those 
without the disease, but also comparable or in some cases higher than individuals with other 
chronic disorders.   When examining the charges associated with IBS treatment and comparing 
them to charges associated with asthma treatment, Ricci and colleagues (2000) found the 
healthcare charges for the former to be comparable to later ($7,547 vs. $7,170 per patient per 
year). However, unlike asthma where charges per patient varied based on severity of symptoms, 
charges for individuals with IBS were uniform throughout the study period with slight increase 
seen at the time of diagnosis.  In their comparison of increase in total all-cause healthcare 
charges from 12-month pre-to-post diagnosis between individuals with IBS-C and migraine 
enrolled in managed care plan, Mitra and colleagues (2011) found individuals with IBS-C to 
have significantly greater increase in total charges than those with migraine.            
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Though several studies have examined the healthcare utilization and costs associated with 
IBS among commercial payers, the information on burden of this disease in Medicaid population 
is limited.  Medicaid is a joint federal-state program that provides health insurance to indigent 
population in the US.  In their study of healthcare utilization and cost assessment among 
individuals with IBS enrolled in California and North Carolina Medicaid programs, Martin and 
colleagues (2003) found ~50% higher healthcare costs among Medicaid recipients with IBS as 
compared to a control group of individuals without IBS.  Expenses associated with office visits 
and prescription drugs contributed towards the cost differential between the two groups.  
Another study conducted to look into the economic burden of treatment failure to the 
Missouri Medicaid for individuals with IBS-C found that ineffectiveness of primary therapy for 
IBS-C led to an additional cost of over $4,000 to Missouri Medicaid compared to patients who 
responded to the initial therapy. Failure to respond to initial therapy resulted in higher healthcare 
resource utilization and led to implementation of more cost-intensive therapies (Guerin et al., 
2014).   
IBS and Comorbidities 
Besides the underlying disorder, individuals with IBS seek care for other GI and extra-intestinal 
complaints. Studies have revealed that IBS and gastroesophageal reflux disease (GERD) have a 
higher frequency of occurrence in combination than expected. One study found half of all 
individuals with IBS to have GERD (Kennedy, Jones, Hungin, O’flanagan, & Kelly, 1998).  A 
study conducted using the Nationwide Emergency Department Sample (NEDS) to examine the 
risk of osteoporosis and osteoporosis-related fractures in individuals with IBS found a 
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significantly greater risk of osteoporosis or related fractures in this group as compared with the 
non-IBS control group (Stobaugh, Deepak, & Ehrenpreis, 2013).     
Although the underlying etiology is unknown, individuals with IBS have been reported to 
have a greater likelihood of developing other disorders like depression, fibromyalgia, and 
migraine. In one study, almost one-third of individuals with IBS were reported to experience 
symptoms similar to that of fibromyalgia (Sperber et al., 1999).  Another study reported that 
fibromyalgia was prevalent in 20% of individuals with IBS (Lubrano et al., 2001).  In a study 
conducted among individuals with IBS enrolled in a health maintenance organization, prevalence 
of psychiatric disorders including depression, anxiety and somatoform disorders was reported to 
be as high as 90% (Whitehead et al., 2007).  A population-based study conducted in Sweden also 
found individuals with IBS to have significantly more psychiatric distress compared to a control 
population (Österberg et al., 2000).  Estimates on the occurrence of comorbid psychiatric 
disorders among individuals with IBS range between 54% and 94%. (Irwin, Falsetti, Lydiard, & 
Ballenger, 1996; Lydiard, Fossey, Marsh, & Ballenger, 1993; Walker, Gelfand, Gelfand, & 
Katon, 1995; Drossman et al., 1988). Studies have observed depression to be the most common 
psychiatric disorder associated with IBS, followed by anxiety (Whitehead, Palsson, & Jones, 
2002).  A cohort study conducted in the UK, using data from 123 general practices in the 
General Practice Research Database (GPRD) reported that patients with IBS have a significantly 
greater frequency of comorbid anxiety and depression than the control group (Jones, Latinovic, 
Charlton, & Gulliford, 2006). 
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Study significance 
Though studies have assessed the healthcare utilization and costs associated with IBS, the burden 
of this disease in Medicaid population is not well understood.  To date, only a couple of studies 
have examined the healthcare use and costs associated with IBS in Medicaid population (Martin 
et al., 2003; Guerin et al., 2014).  In both studies, IBS diagnosis was found to be associated with 
incremental healthcare burden.  These studies provided useful information on the burden of IBS 
in a vulnerable population; however, certain limitations associated with these studies limit their 
usefulness.  First, these studies used limited state Medicaid data, which restricted the 
generalizability of their findings.  Second, the study by Martin et al. (2003) was based on 
Medicaid data from more than a decade ago.  With the expansion of Medicaid program through 
passage of the Patient Protection and Affordable Care Act (PPACA) in 2010, several million 
new enrollees have been added.  With increasing enrollment, it is expected that resource 
utilization associated with chronic diseases including IBS will likely increase over the coming 
years.  As a result, more recent estimates of disease prevalence and healthcare burden would 
assist policy makers in resource allocation decisions.   
As noted in an earlier section, IBS is often accompanied by comorbidities including 
depression, which can further complicate the disease profile and resource use in this population.  
To date, no study has assessed the incremental healthcare utilization and cost impact of comorbid 
depression among individuals with IBS.   
Considering these gaps in the literature, the following objectives for the proposed study 
have been developed: 
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RESEARCH OBJECTIVES 
Objective I – To determine the prevalence of IBS, and comorbid depression among individuals 
with IBS in multi-state Medicaid population. 
 
Considering that there are no estimates of IBS prevalence in Medicaid population, the proposed 
study aims to bridge this important gap in the literature.  Prevalence of IBS will be calculated 
using multi-state Medicaid data.  Further, prevalence will be calculated and reported by different 
demographic categories. Moreover, there are no estimates of prevalence of comorbid depression 
among individuals with IBS in multi-state Medicaid population. An estimate of comorbid 
depression prevalence in this population will not only add to the body of knowledge about the 
relationship between IBS and depression but also aid state Medicaid policy makers make health 
policy decisions in this population of patients.    
Research Questions for Objective I – 
1. What is the prevalence of IBS in the Medicaid population? 
2. What is the prevalence of comorbid depression among adults with IBS in the Medicaid 
population?  
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Objective II – To determine the incremental healthcare burden of comorbid depression among 
individuals with IBS enrolled in Medicaid program.  
Depression is one of the most common psychiatric comorbidities in individuals with IBS 
(Whitehead et al., 2007; Drossman et al., 1988).  Studies in other chronic diseases have 
established the significant economic burden of comorbid depression, in terms of medical costs 
and healthcare resource utilization. For example, a study using the Medical Expenditure Panel 
Survey (MEPS) data, revealed that diabetes patients with comorbid depression had greater 
utilization of ambulatory care services and significantly more prescription medication fills than 
those without comorbid depression (Egede, Zheng, & Simpson, 2002).  Another study that 
looked into healthcare costs for diabetes and congestive heart failure patients enrolled in the fee-
for-service Medicare program, found individuals with comorbid depression to incur greater 
healthcare costs than individuals without comorbid depression (Unützer et al., 2009).         
 
Research Questions for Objective II –  
1. To determine the healthcare resource utilization of individuals with IBS with versus 
without comorbid depression  
2. To determine the healthcare costs for individuals with IBS with versus without comorbid 
depression    
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METHODS 
 
For the purpose of this study, a retrospective, longitudinal, cohort study of the 2006-2008 
Medicaid fee-for-service (FFS) claims database for 39 states was conducted.  Approval was 
taken from the University of Mississippi Institutional Review Board, following which a data use 
agreement (DUA) was made with Center for Medicare and Medicaid Services (CMS) through 
Research Data Assistance Center (ResDAC).    
 
Data Source 
Established in 1965, Medicaid is a joint federal-state funded healthcare program that provides 
medical care insurance coverage to indigent people in the United States (US).  Though Medicaid 
benefits vary among states, these benefits typically cover costs associated with physician and 
hospital visits, emergency room visits, and prescription drugs.  The Center for Pharmaceutical 
Marketing and Management (CPMM) at the University of Mississippi houses the Medicaid data 
for 39 states.  The 2006-2008 Medicaid Analytic Extract (MAX) files for 39 states (all states 
except Alaska, Hawaii, Maine, Missouri, Montana, North Dakota, Pennsylvania, South Dakota, 
Utah, Wisconsin, Wyoming, and District of Columbia) was used for the purpose of the study.   
The MAX data comprises of -  
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1)  The Personal Summary (PS) file, which contains demographic variables (e.g. date of 
birth, gender, race), monthly enrollment status, utilization summary, and eligibility 
information for each of the beneficiaries.  
2)  The inpatient (IP) discharge level file contains detailed information about the enrollees’ 
utilization of inpatient services including International Classification of Diseases, ninth 
revision, clinical modification (ICD-9-CM) diagnosis codes (a maximum of 10 fields of 
diagnosis codes), current procedural terminology fourth edition (CPT-4) or healthcare 
common procedure coding system (HCPCS) procedure codes (a maximum of 7 fields of 
procedure codes), discharge status, length of stay, and amount paid. 
3)  The prescription drug (PD) claims file has information regarding utilization of 
prescription drugs including the date of prescription fill, national drug classification 
(NDC) codes, days of supply, quantity supplied, and amount paid.  
4)  The other therapy (OT) claims file contains records for physician services, lab and clinic 
services, home health, hospice and premium payments.  The outpatient hospital 
institutional claims are also captured in this file.  The claims comprise of information 
about diagnosis codes, procedure codes, and date of service.  The MAX OT file contains 
two fields for diagnosis codes and one field for procedure codes.  
To ensure privacy, de-identified data is made available to study researchers.  A unique common 
identifier will be used to link data files for study purposes.     
 
Objective I 
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Study Sample 
The target population for this objective included recipients who were continuously enrolled in 
Medicaid FFS program for a period of three years from 2006 to 2008, and were greater than or 
equal to 18 years of age as of January 1, 2006 and less than 65 years of age as of December 31, 
2008.  Recipients with one or more claims for long-term care were excluded from study 
analyses.  Recipients aged 65 years and above were also excluded considering that Medicaid is 
not the primary payer for these individuals.  Recipients with irritable bowel syndrome (IBS) 
were identified using the ICD-9-CM code 564.1.  Identification of depression among recipients 
with IBS was based on presence of one or more medical claims for depression (having ICD-9-
CM codes of 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.30, 296.31, 296.32, 
296.33, 296.34, 296.35, 296.36, 296.50, 296.51, 296.52, 296.53, 296.54, 296.55, 296.56, 296.60, 
296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4, 309.1, or 311) in the 
period between 2006 - 2008. 
Moreover, the study also excluded recipients who might have had any claims, either 
primary or secondary, for malignant neoplasm of digestive organs and peritoneum (having ICD-
9-CM codes of  150.0 – 150.5, 150.8 – 150.9, 151.0 – 151.6, 151.8 – 151.9, 152.0 – 152.3, 152.8 
-152.9, 153.0 – 153.9, 154.0 – 154.3, 154.8, 155.0 – 155.2, 156.0 – 156.2, 156.8 – 156.9, 157.0 – 
157.4, 157.8 – 157.9, 158.0, 158.8-158.9, 159.0 – 159.1, 159.8 – 159.9),  inflammatory bowel 
disease that comprises of Crohn’s disease, ulcerative colitis, intestinal vascular insufficiency, or 
non-infectious enteritis and colitis (having ICD-9-CM codes of 555.xx to 558.xx), or 
diverticulosis (having ICD-9-CM codes of 562.01 – 562.03, 562.11 – 562.13) since they can 
confound diagnosis of IBS.  
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Objective II 
Study Sample 
The target population for this objective included recipients who were continuously enrolled in 
Medicaid FFS program for a period of three years from 2006 to 2008, and were greater than or 
equal to 18 years of age as of January 1, 2006 and less than 65 years of age as of December 31, 
2008.  Recipients with one or more claims for long-term care were excluded from study 
analyses.  Recipients aged 65 years and above were also be excluded considering that Medicaid 
is not the primary payer for these individuals.  The study excluded recipients who might have 
had any claims (between 2006-2008), either primary or secondary, for malignant neoplasm of 
digestive organs and peritoneum (having ICD-9-CM codes of 150.0 – 150.5, 150.8 – 150.9, 
151.0 – 151.6, 151.8 – 151.9, 152.0 – 152.3, 152.8 -152.9, 153.0 – 153.9, 154.0 – 154.3, 154.8, 
155.0 – 155.2, 156.0 – 156.2, 156.8 – 156.9, 157.0 – 157.4, 157.8 – 157.9, 158.0, 158.8-158.9, 
159.0 – 159.1, 159.8 – 159.9),  inflammatory bowel disease that comprises of Crohn’s disease, 
ulcerative colitis, intestinal vascular insufficiency, or non-infectious enteritis and colitis (having 
ICD-9-CM codes of 555.xx to 558.xx), or diverticulosis (having ICD-9-CM codes of 562.01 – 
562.03, 562.11 – 562.13) since they can confound diagnosis of IBS.  
Recipients with irritable bowel syndrome (IBS) were identified using the ICD-9-CM 
code 564.1 if they had at least one primary or secondary diagnosis claim for IBS in 2007, and the 
first observed IBS claim was considered as the “index date”.  Recipients with claims for IBS 
were divided into two groups based on the presence of one or more medical claims for 
depression (having ICD-9-CM codes of 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 
296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 296.50, 296.51, 296.52, 296.53, 296.54, 
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296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4, 
309.1, or 311) in the period between 2006 - 2008. Based on this inclusion and exclusion criteria, 
individuals with IBS were classified into two mutually exclusive groups of individuals with IBS 
with comorbid depression (IBS with depression) and individuals with IBS without comorbid 
depression (IBS without depression).  
Study Measures 
Healthcare Utilization and Costs 
The 12-month post-index date all-cause healthcare resource utilization was gauged for the major 
medical service components – inpatient hospital, emergency room (ER), hospital outpatient, 
outpatient physician office, and prescription medications.   
Similarly, IBS-related healthcare costs were also computed, with costs being divided into 
four main categories - inpatient, outpatient, emergency room, and prescription drug.  IBS-related 
medical (inpatient, ER, and outpatient) costs were calculated based on the presence of any 
primary medical claim for irritable colon.  IBS-related prescription drug costs were computed 
based on prescription claims for drugs that are typically used for symptoms of IBS.  These 
include antispasmodics, anxiolytics, bile sequestrants, diphenoxylate, laxatives, loperamide, non-
steroidal anti-inflammatory drugs, opioids, pro-motility agents, selective serotonin-reuptake 
inhibitors, and tricyclic agents.  The medical procedures that are usually employed for diagnosis 
of IBS were considered while calculating the IBS-related healthcare costs.  These procedures 
include flexible sigmoidoscopy, colonoscopy, X-ray – radiography, computerized tomography 
scan, lower-GI series – barium tests, EMA blood tests, lactose breath hydrogen tests, complete 
blood counts, stool tests, and abdominal ultrasound.    
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Other Variables 
Age was determined as of December 31 of each year (2006-2008) in order to ascertain eligibility 
for inclusion each year. While assessing healthcare costs, charlson comorbidity index (CCI) was 
included as a measure of case mix variation between recipients with IBS with depression and 
IBS without depression. The D’Hoore adaptation of CCI was used in the study.  CCI scores for 
the two groups will be calculated for the 12-month pre-index period.  
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DATA ANALYSIS 
Objective I 
Period prevalence rate among adults with IBS was calculated by dividing the number of unique 
recipients with primary or secondary diagnosis of IBS to the number of eligible Medicaid 
recipients for the period of 2006-2008, after imposing the inclusion and exclusion criteria.  Rates 
were stratified by demographic variables (age, race, state, and region of the country). Prevalence 
has been reported as cases per 1,000 Medicaid recipients.
Period prevalence of comorbid depression among adults with IBS was determined by 
dividing the number of unique recipients with claims for both IBS and depression to the total 
number of unique recipients with claims for IBS in the multi-state Medicaid population. 
Prevalence rates were stratified by demographic variables (age, race, state, and region of the 
country). Prevalence has been reported in percentage. 
 
Objective II 
Means and standard deviation or frequency and percentages were used to depict the 
characteristics of the recipients.  All analyses were conducted using the Statistical Analysis 
Software (SAS®) version 9.4 (SAS Institute, Cary, NC).  P values < 0.05 will be considered for 
statistical significance.          
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For each of the medical service components – inpatient, outpatient, emergency room, and 
prescription drugs, a generalized linear model (GLM) with an appropriate distribution and link 
was used to determine the impact of comorbid depression on all-cause and IBS-specific 
healthcare utilization among adults with IBS.  Appropriate distribution (Gaussian, Poisson, 
Gamma, Inverse Gaussian or Wald) of the dependent variable, number of health services used, 
was determined with the help of a Modified Park test (Manning and Mullahy, 2001).  The link 
function of the model was determined using the Pregibon Link test (Pregibon, 1980).  Based on 
the results of these tests, poisson distribution and log link was chosen for the generalized linear 
models.  Since, there was a substantial proportion of zero values for the inpatient and emergency 
room count variables, Vuong test (Vuong, 1989) was used to assess whether the zero inflated 
poisson or the zero inflated negative binomial distributions should be used instead of the 
standard poisson to account for zero-inflation or over dispersion.  Based on the results of the 
Vuong test, zero inflated negative binomial was chosen as the appropriate distribution for all-
cause inpatient, IBS-related inpatient, and all-cause emergency room utilization variables, and 
zero-inflated poisson was chosen as the appropriate distribution for the IBS-related emergency 
room utilization variable.   
To assess the impact of comorbid depression on all-cause and IBS-related healthcare 
costs among adults with IBS, a GLM with an appropriate distribution and link function were 
employed.  To ascertain appropriate distribution of the dependent variable, healthcare cost in this 
case, a Modified Park test was conducted (Manning and Mullahy, 2001).  The link function was 
determined using Pregibon Link test (Pregibon, 1980).  Based on the results of these tests, 
gamma distribution and log link were chosen for each of the eight GLM models for healthcare 
costs.  Due to presence of zero values for costs for some recipients for inpatient and emergency 
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room expenditures, these particular cost measures were estimated using the two-part model.  The 
first part of the model comprised of a logistic regression model to predict the probability of 
observing non-zero costs and the second part of the model was a GLM with gamma distribution 
and log link for recipients with non-zero costs.  Multiplying the probability of non-zero cost from 
the first part with the estimated costs from the second part gave us the final cost estimates.  The 
two part model is usually used when there are many zero values in the data, which is very 
common in healthcare data.  The model adjusts for the zero costs as well as the skewness 
resulting from large cost values to give a reliable estimate of medical costs (Blough et al, 1999).  
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ABSTRACT 
 
Objective: To determine the period prevalence of IBS and comorbid depression among 
individuals with irritable bowel syndrome (IBS) in multi-state Medicaid population, and to 
assess the impact of comorbid depression on healthcare utilization and costs among individuals 
with IBS enrolled in Fee-for-Service Medicaid program.  
 
Methods: A retrospective cohort study was conducted using 2006-2008 Medicaid Analytic 
Extract files for 39 states.  Beneficiaries with IBS were identified based on any medical claims 
for the disease.  Beneficiaries with one or more medical claims for depression during the study 
period were considered to have had comorbid depression.  For each beneficiary, the first claim 
for IBS in 2007 was considered as the index date.  12-month post index date all-cause and IBS-
related healthcare utilization and costs were computed for each of the four medical service 
components – inpatient, outpatient, emergency room, and prescription drug.  Generalized linear 
models were used to assess the impact of comorbid depression on healthcare utilization and 
costs. 
 
Results: The period prevalence of IBS in the population was 4.4 per 1,000 Medicaid 
beneficiaries.  The period prevalence of comorbid depression among beneficiaries with IBS was 
26.88%.  Beneficiaries with IBS and depression had significantly greater all-cause and IBS-
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related inpatient, IBS-related outpatient, all-cause emergency room, all-cause and IBS-related 
prescription drug utilization, and IBS-related outpatient, all-cause and IBS-related emergency 
room, and all-cause and IBS-related prescription drug costs as compared to those without 
depression. 
 
Conclusion: Given the impact on healthcare use and costs, there is a need for better screening 
and management of depression in this population. 
     Keywords: irritable bowel syndrome, depression, healthcare use, healthcare cost, prevalence        
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ECONOMIC BURDEN OF COMORBID DEPRESSION AMONG INDIVIDUALS WITH 
IRRITABLE BOWEL SYNDROME ENROLLED IN FEE-FOR-SERVICE MEDICAID 
 
Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is characterized by 
abdominal pain, bloating, and alternating bowel habits. Based on the symptoms of the disease, 
IBS can be divided into three subtypes – IBS constipation-dominant (IBS-C), IBS diarrhea-
dominant (IBS-D), and IBS alternating between constipation and diarrhea (IBS-M). Among all 
gastrointestinal diseases, IBS has a very high frequency.  At least one in ten primary care visits 
and approximately one-fourth to one-half of gastroenterology referral visits can be attributed to 
IBS.1 
In the United States (US), IBS prevalence varies based on the criteria used for 
determining disease and the study population.  Prevalence for IBS has been estimated to be as 
high as 20%.2  Irrespective of the criteria used, the prevalence for IBS also varies by its 
subtypes.3,4  The prevalence of IBS-M has been reported to be four times that of IBS-C, and 
three times that of IBS-D.3  Prevalence is said to vary by demographic factors including age and 
gender.  In a study conducted by Drossman and colleagues (1993), IBS prevalence was observed 
to be higher among individuals aged less than 45 years as compared to those aged 45 years and 
above.5  As per gender, the prevalence of IBS has been reported to  be 2-3 times as high among 
females as compared to males.5, 6, 7   
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IBS has a marked impact on healthcare use and costs, driven by the variability of disease 
symptoms and uncertain nature of its diagnosis and treatment.  In their study of healthcare 
burden, Talley et al. found the healthcare costs among individuals with IBS to be 1.6 times 
higher than those without IBS.8  Similar results were observed by Levy et al. (2001), who also 
found higher healthcare costs associated with IBS diagnosis.9 Besides causing considerable 
health and economic burden, IBS also adversely impacts work productivity and increase in work 
absenteeism.10   
Though studies have assessed the healthcare utilization and costs associated with IBS, the 
burden of this disease in Medicaid population is not well understood.  To date, only a couple of 
studies have examined the healthcare use and costs associated with IBS in Medicaid 
population.11, 12  In both studies, IBS diagnosis was found to be associated with incremental 
healthcare burden.  These studies provided useful information on the burden of IBS in a 
vulnerable population; however, certain limitations associated with these studies limit their 
usefulness.  First, these studies used limited state Medicaid data, which restricted the 
generalizability of their findings.  Second, the study by Martin et al. was based on Medicaid data 
from more than a decade ago.  With the expansion of Medicaid program through passage of the 
Patient Protection and Affordable Care Act (PPACA) in 2010, several million new enrollees 
have been added.  With increasing enrollment, it is expected that resource utilization associated 
with chronic diseases including IBS will likely increase over the coming years.  As a result, more 
recent estimates of disease prevalence and healthcare burden would assist policy makers in 
resource allocation decisions.  Estimates on the occurrence of comorbid psychiatric disorders 
among individuals with IBS range between 54% and 94%.13, 14, 15  Studies have observed 
depression to be the most common psychiatric disorder associated with IBS, followed by 
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anxiety.16  IBS is often accompanied by comorbidities including depression, which can further 
complicate the disease profile and resource use in this population.  
Studies in other chronic diseases have established the significant economic burden of 
comorbid depression, in terms of medical costs and healthcare resource utilization. For example, 
a study using the Medical Expenditure Panel Survey (MEPS) data, revealed that diabetes patients 
with comorbid depression had greater utilization of ambulatory care services and significantly 
more prescription medication fills than those without comorbid depression.17  Another study that 
looked into healthcare costs for diabetes and congestive heart failure patients enrolled in the fee-
for-service Medicare program, found individuals with comorbid depression to incur greater 
healthcare costs than individuals without comorbid depression.18  
Study significance 
Considering that there are no estimates of IBS prevalence in multi-state Medicaid population, 
one of the objectives of the study was to estimate the prevalence of IBS in multi-state Medicaid 
population.  Moreover, given that there are no estimates of prevalence of comorbid depression 
among individuals with IBS in multi-state Medicaid population, the study aimed to determine the 
prevalence of comorbid depression among recipients with IBS in the multi-state Medicaid 
population.  Additionally, no previous study has assessed the incremental healthcare utilization 
and cost impact of comorbid depression among individuals with IBS in this population.  This 
study aimed to estimate the impact of comorbid depression on healthcare utilization and 
expenditures among individuals with IBS in the multi-state Medicaid population.  
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Study Methodology 
For the purpose of this study, a retrospective, longitudinal, cohort study of the 2006-2008 
Medicaid fee-for-service (FFS) claims database for 39 states (Alabama, Arizona, Arkansas, 
California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana,  Iowa, 
Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, 
Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North 
Carolina, Ohio, Oklahoma, Oregon, Rhode Island, South Carolina, Tennessee, Texas, Vermont, 
Virginia, Washington, and West Virginia) was conducted.  Approval was taken from the 
University of Mississippi Institutional Review Board, following which a data use agreement 
(DUA) was made with Center for Medicare and Medicaid Services (CMS) through Research 
Data Assistance Center (ResDAC).    
Data Source 
Established in 1965, Medicaid is a joint federal-state funded healthcare program that provides 
medical care insurance coverage to indigent people in the United States (US).  Though Medicaid 
benefits vary among states, these benefits typically cover costs associated with physician and 
hospital visits, emergency room visits, and prescription drugs.  The 2006-2008 Medicaid 
Analytic Extract (MAX) files for 39 states was used for the purpose of the study.   The MAX 
data comprises of -  
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1)  The Personal Summary (PS) file, which contains demographic variables (e.g. date of 
birth, gender, race), monthly enrollment status, utilization summary, and eligibility 
information for each of the beneficiaries.  
2)  The inpatient (IP) discharge level file contains detailed information about the enrollees’ 
utilization of inpatient services including International Classification of Diseases, ninth 
revision, clinical modification (ICD-9-CM) diagnosis codes (a maximum of 10 fields of 
diagnosis codes), current procedural terminology fourth edition (CPT-4) or healthcare 
common procedure coding system (HCPCS) procedure codes (a maximum of 7 fields of 
procedure codes), discharge status, length of stay, and amount paid. 
3)  The prescription drug (PD) claims file has information regarding utilization of 
prescription drugs including the date of prescription fill, national drug classification 
(NDC) codes, days of supply, quantity supplied, and amount paid.  
4)  The other therapy (OT) claims file contains records for physician services, lab and clinic 
services, home health, hospice and premium payments.  The outpatient hospital 
institutional claims are also captured in this file.  The claims comprise of information 
about diagnosis codes, procedure codes, and date of service.  The MAX OT file contains 
two fields for diagnosis codes and one field for procedure codes.  
Study Sample 
Determination of prevalence of IBS and comorbid depression among adults with IBS   
The target population for this objective included recipients who were continuously enrolled in 
Medicaid FFS program for a period of three years from 2006 to 2008, and were greater than or 
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equal to 18 years of age as of January 1, 2006 and less than 65 years of age as of December 31, 
2008.  Recipients with one or more claims for long-term care were excluded from study 
analyses.  Recipients aged 65 years and above were also excluded considering that Medicaid is 
not the primary payer for these individuals.  Recipients with irritable bowel syndrome (IBS) 
were identified using the ICD-9-CM code 564.1.  Identification of depression among recipients 
with IBS was based on presence of one or more medical claims for depression (having ICD-9-
CM codes of 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 296.30, 296.31, 296.32, 
296.33, 296.34, 296.35, 296.36, 296.50, 296.51, 296.52, 296.53, 296.54, 296.55, 296.56, 296.60, 
296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4, 309.1, or 311) in the 
period between 2006 - 2008. 
Moreover, the study also excluded recipients who might have had any claims, either 
primary or secondary, for malignant neoplasm of digestive organs and peritoneum (having ICD-
9-CM codes of  150.0 – 150.5, 150.8 – 150.9, 151.0 – 151.6, 151.8 – 151.9, 152.0 – 152.3, 152.8 
-152.9, 153.0 – 153.9, 154.0 – 154.3, 154.8, 155.0 – 155.2, 156.0 – 156.2, 156.8 – 156.9, 157.0 – 
157.4, 157.8 – 157.9, 158.0, 158.8-158.9, 159.0 – 159.1, 159.8 – 159.9),  inflammatory bowel 
disease that comprises of Crohn’s disease, ulcerative colitis, intestinal vascular insufficiency, or 
non-infectious enteritis and colitis (having ICD-9-CM codes of 555.xx to 558.xx), or 
diverticulosis (having ICD-9-CM codes of 562.01 – 562.03, 562.11 – 562.13) since they can 
confound diagnosis of IBS.   
Impact of comorbid depression on healthcare utilization and costs 
The target population for this objective included recipients who were continuously enrolled in 
Medicaid FFS program for a period of three years from 2006 to 2008, and were greater than or 
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equal to 18 years of age as of January 1, 2006 and less than 65 years of age as of December 31, 
2008.  Recipients with one or more claims for long-term care were excluded from study 
analyses.  Recipients aged 65 years and above were also be excluded considering that Medicaid 
is not the primary payer for these individuals.  The study excluded recipients who might have 
had any claims (between 2006-2008), either primary or secondary, for malignant neoplasm of 
digestive organs and peritoneum (having ICD-9-CM codes of 150.0 – 150.5, 150.8 – 150.9, 
151.0 – 151.6, 151.8 – 151.9, 152.0 – 152.3, 152.8 -152.9, 153.0 – 153.9, 154.0 – 154.3, 154.8, 
155.0 – 155.2, 156.0 – 156.2, 156.8 – 156.9, 157.0 – 157.4, 157.8 – 157.9, 158.0, 158.8-158.9, 
159.0 – 159.1, 159.8 – 159.9),  inflammatory bowel disease that comprises of Crohn’s disease, 
ulcerative colitis, intestinal vascular insufficiency, or non-infectious enteritis and colitis (having 
ICD-9-CM codes of 555.xx to 558.xx), or diverticulosis (having ICD-9-CM codes of 562.01 – 
562.03, 562.11 – 562.13) since they can confound diagnosis of IBS.  
Recipients with irritable bowel syndrome (IBS) were identified using the ICD-9-CM 
code 564.1 if they had at least one primary or secondary diagnosis claim for IBS in 2007, and the 
first observed IBS claim was considered as the “index date”.  Recipients with claims for IBS 
were divided into two groups based on the presence of one or more medical claims for 
depression (having ICD-9-CM codes of 296.20, 296.21, 296.22, 296.23, 296.24, 296.25, 296.26, 
296.30, 296.31, 296.32, 296.33, 296.34, 296.35, 296.36, 296.50, 296.51, 296.52, 296.53, 296.54, 
296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.89, 298.0, 300.4, 
309.1, or 311) in the period between 2006 - 2008. Based on this inclusion and exclusion criteria, 
individuals with IBS were classified into two mutually exclusive groups of individuals with IBS 
with comorbid depression (IBS with depression) and individuals with IBS without comorbid 
depression (IBS without depression).  
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Study Measures 
The 12-month post-index date all-cause healthcare resource utilization was gauged for the major 
medical service components – inpatient hospital, emergency room (ER), hospital outpatient, 
outpatient physician office, and prescription medications.   
Similarly, IBS-related healthcare costs were also computed, with costs being divided into 
four main categories - inpatient, outpatient, emergency room, and prescription drug.  IBS-related 
medical (inpatient, ER, and outpatient) utilization and costs were calculated based on the 
presence of any primary medical claim for irritable colon.  IBS-related prescription drug 
utilization and costs were computed based on prescription claims for drugs that are typically used 
for symptoms of IBS.  These include antispasmodics, anxiolytics, bile sequestrants, 
diphenoxylate, laxatives, loperamide, non-steroidal anti-inflammatory drugs, opioids, pro-
motility agents, selective serotonin-reuptake inhibitors, and tricyclic agents.  The medical 
procedures that are usually employed for diagnosis of IBS were considered while calculating the 
IBS-related healthcare utilization and costs.  These procedures include flexible sigmoidoscopy, 
colonoscopy, X-ray – radiography, computerized tomography scan, lower-GI series – barium 
tests, EMA blood tests, lactose breath hydrogen tests, complete blood counts, stool tests, and 
abdominal ultrasound.   
Age was determined as of December 31 of each year (2006-2008) in order to ascertain 
eligibility for inclusion each year. While assessing healthcare costs, charlson comorbidity index 
(CCI) was included as a measure of case mix variation between recipients with IBS with 
depression and IBS without depression. The D’Hoore adaptation of CCI was used in the study.  
CCI scores for the two groups will be calculated for the 12-month pre-index period.  
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Statistical Analysis 
Period prevalence rate among adults with IBS was calculated by dividing the number of unique 
recipients with primary or secondary diagnosis of IBS to the number of eligible Medicaid 
recipients for the period of 2006-2008, after imposing the inclusion and exclusion criteria.  Rates 
were stratified by demographic variables (age, race, state, and region of the country). Prevalence 
has been reported as cases per 1,000 Medicaid recipients.  
Period prevalence of comorbid depression among adults with IBS was determined by 
dividing the number of unique recipients with claims for both IBS and depression to the total 
number of unique recipients with claims for IBS in the multi-state Medicaid population. 
Prevalence rates were stratified by demographic variables (age, race, state, and region of the 
country). Prevalence has been reported in percentage. 
Means and standard deviation or frequency and percentages were used to depict the 
characteristics of the recipients.  All analyses were conducted using the Statistical Analysis 
Software (SAS®) version 9.4 (SAS Institute, Cary, NC).  P values < 0.05 will be considered for 
statistical significance.          
For each of the medical service components – inpatient, outpatient, emergency room, and 
prescription drugs, a generalized linear model (GLM) with an appropriate distribution and link 
was used to determine the impact of comorbid depression on all-cause and IBS-specific 
healthcare utilization among adults with IBS.  Appropriate distribution (Gaussian, Poisson, 
Gamma, Inverse Gaussian or Wald) of the dependent variable, number of health services used, 
was determined with the help of a Modified Park test.19  The link function of the model was 
determined using the Pregibon Link test.20  Based on the results of these tests, poisson 
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distribution and log link was chosen for the generalized linear models.  Since, there was a 
substantial proportion of zero values for the inpatient and emergency room count variables, 
Vuong test21 was used to assess whether the zero inflated poisson or the zero inflated negative 
binomial distributions should be used instead of the standard poisson to account for zero-
inflation or over dispersion.  Based on the results of the Vuong test, zero inflated negative 
binomial was chosen as the appropriate distribution for all-cause inpatient, IBS-related inpatient, 
and all-cause emergency room utilization variables, and zero-inflated poisson was chosen as the 
appropriate distribution for the IBS-related emergency room utilization variable.  
To assess the impact of comorbid depression on all-cause and IBS-related healthcare 
costs among adults with IBS, a GLM with an appropriate distribution and link function were 
employed.  To ascertain appropriate distribution of the dependent variable, healthcare cost in this 
case, a Modified Park test was conducted.19  The link function was determined using Pregibon 
Link test.20  Based on the results of these tests, gamma distribution and log link were chosen for 
each of the eight GLM models for healthcare costs.  Due to presence of zero values for costs for 
some recipients for inpatient and emergency room expenditures, these particular cost measures 
were estimated using the two-part model.  The first part of the model comprised of a logistic 
regression model to predict the probability of observing non-zero costs and the second part of the 
model was a GLM with gamma distribution and log link for recipients with non-zero costs.  
Multiplying the probability of non-zero cost from the first part with the estimated costs from the 
second part gave us the final cost estimates.  The two part model is usually used when there are 
many zero values in the data, which is very common in healthcare data.  The model adjusts for 
the zero costs as well as the skewness resulting from large cost values to give a reliable estimate 
of medical costs.22      
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Study results 
Table 1. Demographic and baseline characteristics
 
Variables IBS only group (n=1450) IBS + Depression group 
(n=533) 
p-value 
Race, n (%)   <0.001 
Caucasians 994 (68.55) 444 (83.30)  
African-Americans 142 (9.79) 45 (8.44)  
Others 314 (21.66) 44 (8.26)  
Region, n (%)   <0.001 
North-east 701 (48.34) 111 (20.83)  
South 505 (34.83) 258 ( 48.41)  
Mid-west 225 (15.52) 158 (29.64)  
West 19 (1.31) 6 (1.13)  
Gender, n (%)   <0.001 
Female 1179 (81.31) 477 (89.49)  
Male 271 (18.69) 56 (10.51)  
Age, mean (sd)  46.41 (10.82) 46.61 (11.81)  0.734 
CCI score, mean (sd) 1.47 (1.95) 1.39 (1.72) 0.412 
Healthcare utilization, mean 
(sd) 
   
All-cause inpatient 0.75 (1.74) 1.02 (2.21) 0.004 
IBS-related inpatient 0.20 (0.57) 0.29 (0.65) 0.002 
All-cause outpatient 157.12 (212.77) 174.09 (207.36) 0.113 
IBS-related outpatient 6.12 (16.92) 10.78 (65.29) 0.012 
All-cause emergency 
room 
2.36 (4.79) 5.63 (8.92) <0.001 
IBS-related emergency 
room 
0.04 (0.25) 0.08 (0.32) 0.026 
All-cause prescription 
drugs 
82.74 (66.47) 102.53 (68.36) <0.001 
IBS-related prescription 
drugs 
11.39 (12.11) 13.94 (11.12) <0.001 
Healthcare cost, mean (sd)    
All-cause inpatient 5358.97 (16810.87) 5510.78 (15574.12) 0.856 
IBS-related inpatient 1174.70 (4362.96) 1397.35 (3939.12) 0.302 
All-cause outpatient 16069.67 (27902.91) 13990.02 (20062.53) 0.115 
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IBS-related outpatient 370.03 (2297.88) 588.20 (3488.29) 0.107 
All-cause emergency 
room 
257.06 (1118.35) 832.23 (2108.03) <0.001 
IBS-related emergency 
room 
6.16 (89.66) 14.08 (155.67) 0.16 
All-cause prescription 
drugs 
7146.52 (7652.25) 7835.62 (7863.77) 0.078 
IBS-related prescription 
drugs 
477.78 (775.44) 528.80 (836.14) 0.204 
 
A total of 1,983 IBS patients were included in the study (1,450 patients in the IBS only group 
and 533 patients in the IBS and depression group). The mean age of patients in the IBS group 
(46 ± 11) was similar to that of the patients in the IBS and depression group (47 ± 12). Patients 
in the two groups had similar comorbidity scores (CCI score of 1.47 for the IBS only group and 
1.39 for the IBS and depression group). Patients in the IBS and depression group had a 
significantly greater proportion of females as compared to patients in the IBS only group (89.5% 
vs 81.3%, P<0.001). Moreover, the two groups differed significantly on race and the region of 
the country that they are from. Additionally, the IBS and depression group had a significantly 
greater mean utilization of all-cause inpatient admissions, IBS-related inpatient admissions, IBS-
related outpatient visits, all-cause and IBS-related emergency room admissions, and all-cause 
and IBS-related prescription drug fills than the IBS only group. (Table 1)  
 
Prevalence of IBS among Medicaid beneficiaries across the 39 state Medicaid programs 
Table 2. Prevalence of IBS in the Medicaid population 
 Rate per 1,000 Medicaid beneficiaries 
Unadjusted prevalence rate 4.4 
Adjusted prevalence rates  
Adjusting for region  
North-east 6.2 
South 7.5 
Mid-west 7.1 
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West 0.2 
Adjusting for race  
Caucasians 9.0 
African Americans 2.8 
Others 1.6 
Adjusting for gender  
Female 5.1 
Male 2.6 
Adjusting for age  
18-25 1.6 
26-35 2.1 
36-45 4.0 
46-55 8.1 
56-65 9.0 
 
Out of 449,690 beneficiaries that were eligible for the study, 1,983 had a diagnosis of IBS. The 
unadjusted prevalence rate of IBS in the Medicaid population was 4.4 per 1,000 Medicaid 
beneficiaries. Adjusting for region, we found the prevalence rate of IBS to vary from 7.5 for 
beneficiaries from the North-eastern states to 0.2 for beneficiaries from the Western states per 
1,000 Medicaid beneficiaries (Table 2). Adjusting for race, we noticed that prevalence rates 
varied based on race, with Caucasians having the highest prevalence of IBS (9.2 per 1,000 
Medicaid beneficiaries). Gender-adjusted estimates of prevalence revealed that IBS prevalence 
was twice as much in females as in males (5.1 vs 2.6, per 1,000 Medicaid beneficiaries). 
Adjusting for age, we found that beneficiaries who were 46 years old or older had the greatest 
prevalence of IBS (8.1 and 9.0 per 1,000 Medicaid beneficiaries for beneficiaries in the age 
groups 46-55 and 56-65 respectively). 
 
Prevalence of comorbid depression among Medicaid beneficiaries with IBS 
Table 3. Prevalence of comorbid depression among beneficiaries with IBS  
 Prevalence rate (%) 
Unadjusted prevalence 26.88 
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 Prevalence rate (%) 
Adjusted prevalence  
Adjusting for region  
North-east 13.67 
South 33.81 
Mid-west 41.25 
West 24.00 
Adjusting for race  
Caucasians 30.88 
African Americans 24.06 
Others 12.29 
Adjusting for gender  
Male 17.13 
Female 28.80 
Adjusting for age  
18-25 23.08 
26-35 24.25 
36-45 31.38 
46-55 28.55 
56-65 23.40 
 
Out of the 1,983 IBS patients that had been included in the study, 533 patients also had a 
diagnosis of depression. The unadjusted prevalence of comorbid depression among beneficiaries 
with IBS was 26.9% (Table 3). Adjusting for region, race, gender, and age we found that IBS 
patients from the Mid-western states had the highest prevalence of comorbid depression (41.3%), 
Caucasians had a higher prevalence of comorbid depression as compared to beneficiaries from 
other races (30.9% vs 24.1% and 12.3%), females had a higher prevalence of comorbid 
depression as compared to males (28.8% vs 17.1%), and beneficiaries in the 36-45 age group had 
a higher prevalence of comorbid depression (31.4%) than beneficiaries in other age groups 
(Table 3). 
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Impact of comorbid depression on healthcare utilization among beneficiaries with IBS 
Table 4. Comparison of healthcare utilization among the two groups 
Type of utilization P-value
Adjusted Mean Lower 95% CI Upper 95% CI Adjusted Mean Lower 95% CI Upper 95% CI
All-cause inpatient 1.058 0.729 1.535 0.689 0.453 1.051 0.001
IBS-specific inpatient
0.251 0.138 0.455 0.133 0.08 0.22 <0.0005
All-cause outpatient 144.071 142.024 146.147 143.193 141.345 145.065 0.134
IBS-specific 
outpatient 8.045 7.633 8.479 5.411 5.161 5.673 <0.0005
All-cause ER 3.876 3.01 4.989 2.055 1.568 2.693 <0.0005
IBS-specific ER 0.391 0.161 0.948 0.527 0.256 1.085 0.497
All-cause 
prescription drugs 66.599 65.141 68.091 57.059 55.879 58.262 <0.0005
IBS-specific 
prescription drugs 9.543 8.999 10.119 7.83 7.409 8.275 <0.0005
IBS and depression group IBS only group
95% Confidence Interval 95% Confidence Interval
 
A comparison of mean healthcare utilization among beneficiaries with IBS and beneficiaries 
with IBS and depression is presented in Table 4. After adjusting for age, gender, region, other 
comorbidities, and race, patients with IBS and depression had more all-cause inpatient visits 
(1.06 vs 0.69, P = 0.001), IBS-specific inpatient visits (0.25 vs 0.13, P<0.001), IBS-specific 
outpatient visits (8.04 vs 5.41, P<0.001), and all-cause emergency room admissions (3.88 vs 
2.06, P<0.001) than IBS patients without depression. Additionally, beneficiaries with IBS and 
depression had more all-cause prescription fills (66.6 vs 57.1, P<0.001) and IBS-specific 
prescription fills (9.54 vs 7.83, P<0.001) than their non-depressed counterparts. We did not find 
any statistically significant differences between the two groups in the mean number of all-cause 
outpatient visits and IBS-specific emergency room admissions.  
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Impact of comorbid depression on healthcare costs among beneficiaries with IBS 
Table 5. Comparison of healthcare costs among the two groups 
Type of cost P-value
Adjusted Mean Lower 95% CI Upper 95% CI Adjusted Mean Lower 95% CI Upper 95% CI
All-cause inpatient 
(in US $) 4,833 3,776 6,187 3,316 2,602 4,226 0.284
IBS-specific inpatient 
(in US $) 1,060 771 1,457 685 498 942 0.736
All-cause outpatient 
(in US $) 14,468 12,322 16,987 16,000 13,900 18,417 0.105
IBS-specific 
outpatient (in US $) 608 506 730 448 385 521 <0.0005
All-cause ER (in US 
$) 403 318 511 142 115 175 <0.0005
IBS-specific ER (in 
US $) 13 7 23 3 2 5 <0.0005
All-cause prescription 
drug (in US $)
4,738 4,104 5,469 4,168 3,674 4,728 0.011
IBS-specific 
prescription drug (in 
US $) 347 282 426 291 242 351 0.016
IBS and depression group IBS only group
95% Confidence Interval 95% Confidence Interval
 
A comparison of mean healthcare expenditures among individuals with IBS and individuals with 
IBS and depression is shown in Table 5. After adjusting for covariates, we found that individuals 
with IBS and depression incurred more expenditures on IBS-related outpatient visits ($608 vs 
$448, P<0.001), all-cause emergency room admissions ($403 vs $142, P<0.001) and IBS-related 
emergency room admissions ($13 vs $3, P<0.001) than those with IBS but without depression. 
Moreover, individuals with IBS and depression had significantly higher all-cause prescription 
drug cost ($4,738 vs $4,168, P=0.011) and IBS-related prescription drug cost ($347 vs $291, P = 
0.016) than their non-depressed counterparts with IBS. We did not find statistically significant 
differences in any other expenditure category.  
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Discussion 
To the best of our knowledge, this is the first study to report prevalence rates, prevalence of 
comorbid depression, and the impact of depression on all-cause and IBS-specific inpatient, 
outpatient, emergency room, and prescription drug utilization and costs among adults with IBS 
using multi-state Medicaid claims data.  
A total of 1,983 Medicaid beneficiaries had a diagnosis of IBS across the 39 state 
Medicaid programs in the period between 2006 and 2008. The period prevalence rate of IBS was 
4.4 per 1,000 Medicaid beneficiaries.  Our IBS prevalence estimates are lower than the treated 
prevalence rates seen in published literature.11  This can be due to several reasons.  One, study 
only included beneficiaries that were continuously enrolled in the Medicaid Fee-for-Service 
program for the entire study period (2006-2008).  Two, the study excluded Medicaid 
beneficiaries that were enrolled in long term care or had dual eligibility in Medicaid and 
Medicare.  Our prevalence estimates are also much lower than the 10-15% estimated by 
population-based surveys.  This can be attributed to various methodological factors. It is not 
possible to detect IBS cases that are not diagnosed, or are misdiagnosed or miscoded from a 
claims-based analysis.  Additionally, the study excluded beneficiaries with any claim for 
malignant neoplasm of digestive organs and peritoneum, inflammatory bowel disease, or 
diverticulosis.  Moreover, it has been reported that majority of the patients with IBS do not seek 
healthcare.23  These factors may have led to an underestimation of IBS prevalence rates in the 
study.   
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The prevalence of comorbid depression among beneficiaries with IBS across the 39 state 
Medicaid programs between 2006 and 2008 was 26.9%.  The prevalence of comorbid depression 
was similar to those found in previous studies.  A study by Thijssen et al.24 reported presence of 
comorbid depression in 22% of IBS patients.  Another study by Whitehead et al.25 found a 30.5% 
prevalence of comorbid depression among IBS patients.  Martin et al.11 noted a prevalence of 
12% and 19.3% of comorbid depression in California and North Carolina state Medicaids.  
Among each gender females with IBS had a greater prevalence of comorbid depression than 
males with IBS.  This finding is similar to that of the study by Thijssen et al.24 who reported a 
higher prevalence of depressive symptoms among males with IBS than females with IBS.  
No study has previously examined the impact of comorbid depression on healthcare 
utilization and expenditures among individuals with IBS.  This study assessed the impact of 
comorbid depression on healthcare utilization and costs on each of the four major healthcare 
service components – inpatient, outpatient, emergency room, and prescription drugs, in order to 
help identify drivers of healthcare utilization and costs in this patient population.   Beneficiaries 
with depression had more all-cause and IBS-specific inpatient, IBS-specific outpatient, all-cause 
emergency room, all-cause and IBS-specific prescription drug utilization than their non-
depressed counterparts.  This is similar to the results of previous studies that have looked at the 
impact of comorbid depression on the general population and other chronic diseases.  A study by 
Egede et al.17 reported significantly greater office visits and prescription drug use for individuals 
with depression as compared to those without depression in a cohort of diabetes patients.  
Another study by Himmelhoch et al.26 that looked at the impact of comorbid depression on 
emergency department and inpatient hospitalization utilization among Medicare beneficiaries 
with chronic medical conditions noted that patients with depression were more than two times as 
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likely to use emergency department and inpatient hospital services as compared to those without 
depression.   
Moreover, we found that beneficiaries with depression had more IBS-specific outpatient, 
all-cause and IBS-specific emergency room, all-cause and IBS-specific prescription drug 
expenditures than those without depression.  This is similar to that found in previous studies with 
comorbid depression.  Egede et al.17 observed that diabetes patients with depression had 
significantly more total healthcare and prescription drug expenditures than those without 
depression.  A study that examined healthcare costs associated with anxiety and depressive 
disorders in primary care reported that primary care patients with anxiety or depressive disorders 
had significantly greater healthcare costs than those without.27  Another study that compared 
healthcare costs among depressed and non-depressed patients with either diabetes, congestive 
heart failure or both in Fee-for-Service Medicare found significantly greater healthcare costs 
associated with the depressed group as compared with the non-depressed group.18      
The findings of this study not only supports previous studies with respect to the economic 
burden of comorbid depression but also significantly adds to the knowledge base about the 
relationship between IBS and comorbid depression.  Based on the result of this study, it seems 
that there is a need for better depression screening and management among adults with IBS.  
This is of great importance considering the high prevalence of comorbid depression in this 
population and the markedly greater healthcare utilization and expenditure associated with 
depression.  A study that assessed the efficacy of an intervention program geared towards 
improving depression outcomes among patients with diabetes and comorbid depression found 
that compared to the control group, the patients in the intervention group had significantly lower 
healthcare costs and showed improvement in depression outcomes.28  
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Limitations 
This study has a few limitations.  The identification of IBS and depression was based on ICD-9-
CM diagnostic codes, and incorrect coding of the codes may lead to biased study results. It has 
been seen that only a small proportion of the individuals with IBS seek medical care. The fact 
that only the more severe individuals with disease seek medical care, may have overestimated 
the healthcare resource use and cost estimates borne out of the analysis.  Moreover, inherent 
limitations of studies using administrative claims databases apply to this study as well. Also, as 
in all observational studies, claims regarding causation cannot be made. We cannot infer that the 
increased healthcare utilization and expenditures among the depressed group was solely due to 
depression.   Additionally, Medicaid coverage differs from one state to another and disparities in 
different state Medicaid coverage may have affected the results of this study.  Finally, the results 
of this study cannot be generalized beyond the Medicaid Fee-for-Service population.  
 
Conclusion 
This is the first study to have assessed the prevalence of IBS, prevalence of comorbid depression, 
and the impact of comorbid depression on healthcare utilization and costs among adults with 
IBS, enrolled across several state Medicaid programs.  This is also the first study to look into the 
economic burden of comorbid depression among adults with IBS.  The results of this study show 
that comorbid depression has a significant impact on healthcare utilization and costs among 
individuals with IBS. Given the high prevalence of comorbid depression among individuals with 
IBS and the significantly greater healthcare utilization and costs incurred by those with comorbid 
depression as compared to the non-depressed group, there is an immediate need for improvement 
in depression screening and management in this population. 
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SUMMARY & CONCLUSIONS 
To the best of our knowledge, this is the first study to report prevalence rates, prevalence of 
comorbid depression, and the impact of depression on all-cause and Irritable Bowel Syndrome-
specific (IBS-specific) inpatient, outpatient, emergency room, and prescription drug utilization 
and costs among adults with IBS using multi-state Medicaid claims data.  This study showed that 
not only did the beneficiaries with IBS in the multi state Medicaid population have a very high 
prevalence of comorbid depression but also that beneficiaries with depression had more all-cause 
and IBS-specific inpatient, IBS-specific outpatient, all-cause emergency room, all-cause and 
IBS-specific prescription drug utilization than their non-depressed counterparts.  Additionally, 
the study found that beneficiaries with depression had more IBS-specific outpatient, all-cause 
and IBS-specific emergency room, all-cause and IBS-specific prescription drug expenditures 
than those without depression.  This study significantly adds to the knowledge base about the 
relationship between IBS and comorbid depression.  Based on the result of this study, it seems 
that there is a need for better depression screening and management among adults with IBS.  
This is of great importance considering the high prevalence of comorbid depression in this 
population and the markedly greater healthcare utilization and expenditure associated with 
depression. 
The results of this study show that comorbid depression has a significant impact on healthcare 
utilization and costs among individuals with IBS. Given the high prevalence of comorbid 
depression among individuals with IBS and the significantly greater healthcare utilization and 
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costs incurred by those with comorbid depression as compared to the non-depressed group, there 
is an immediate need for improvement in depression screening and management in this 
population.  Future studies should examine the association between comorbid depression and 
healthcare utilization and costs among individuals with IBS in other populations to gain a better 
understanding of the economic burden of comorbid depression among individuals with IBS. 
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Table 1. Demographic and baseline characteristics 
 
Variables IBS only group (n=1450) IBS + Depression group 
(n=533) 
p-value 
Race, n (%)   <0.001 
Caucasians 994 (68.55) 444 (83.30)  
African-Americans 142 (9.79) 45 (8.44)  
Others 314 (21.66) 44 (8.26)  
Region, n (%)   <0.001 
North-east 701 (48.34) 111 (20.83)  
South 505 (34.83) 258 ( 48.41)  
Mid-west 225 (15.52) 158 (29.64)  
West 19 (1.31) 6 (1.13)  
Gender, n (%)   <0.001 
Female 1179 (81.31) 477 (89.49)  
Male 271 (18.69) 56 (10.51)  
Age, mean (sd)  46.41 (10.82) 46.61 (11.81)  0.734 
CCI score, mean (sd) 1.47 (1.95) 1.39 (1.72) 0.412 
Healthcare utilization, mean 
(sd) 
   
All-cause inpatient 0.75 (1.74) 1.02 (2.21) 0.004 
IBS-related inpatient 0.20 (0.57) 0.29 (0.65) 0.002 
All-cause outpatient 157.12 (212.77) 174.09 (207.36) 0.113 
IBS-related outpatient 6.12 (16.92) 10.78 (65.29) 0.012 
All-cause emergency 
room 
2.36 (4.79) 5.63 (8.92) <0.001 
IBS-related emergency 
room 
0.04 (0.25) 0.08 (0.32) 0.026 
All-cause prescription 
drugs 
82.74 (66.47) 102.53 (68.36) <0.001 
IBS-related prescription 
drugs 
11.39 (12.11) 13.94 (11.12) <0.001 
Healthcare cost, mean (sd)    
All-cause inpatient 5358.97 (16810.87) 5510.78 (15574.12) 0.856 
IBS-related inpatient 1174.70 (4362.96) 1397.35 (3939.12) 0.302 
All-cause outpatient 16069.67 (27902.91) 13990.02 (20062.53) 0.115 
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IBS-related outpatient 370.03 (2297.88) 588.20 (3488.29) 0.107 
All-cause emergency 
room 
257.06 (1118.35) 832.23 (2108.03) <0.001 
IBS-related emergency 
room 
6.16 (89.66) 14.08 (155.67) 0.16 
All-cause prescription 
drugs 
7146.52 (7652.25) 7835.62 (7863.77) 0.078 
IBS-related prescription 
drugs 
477.78 (775.44) 528.80 (836.14) 0.204 
 
 
Table 2. Prevalence of IBS in the Medicaid population 
 Rate per 1,000 Medicaid beneficiaries 
Unadjusted prevalence rate 4.4 
Adjusted prevalence rates  
Adjusting for region  
North-east 6.2 
South 7.5 
Mid-west 7.1 
West 0.2 
Adjusting for race  
Caucasians 9.0 
African Americans 2.8 
Others 1.6 
Adjusting for gender  
Female 5.1 
Male 2.6 
Adjusting for age  
18-25 1.6 
26-35 2.1 
36-45 4.0 
46-55 8.1 
56-65 9.0 
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Table 3. Prevalence of comorbid depression among beneficiaries with IBS  
 Prevalence rate (%) 
Unadjusted prevalence 26.88 
Adjusted prevalence  
Adjusting for region  
North-east 13.67 
South 33.81 
Mid-west 41.25 
West 24.00 
Adjusting for race  
Caucasians 30.88 
African Americans 24.06 
Others 12.29 
Adjusting for gender  
Male 17.13 
Female 28.80 
Adjusting for age  
18-25 23.08 
26-35 24.25 
36-45 31.38 
46-55 28.55 
56-65 23.40 
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Table 4. Comparison of healthcare utilization among the two groups 
Type of utilization P-value
Adjusted Mean Lower 95% CI Upper 95% CI Adjusted Mean Lower 95% CI Upper 95% CI
All-cause inpatient 1.058 0.729 1.535 0.689 0.453 1.051 0.001
IBS-specific inpatient
0.251 0.138 0.455 0.133 0.08 0.22 <0.0005
All-cause outpatient 144.071 142.024 146.147 143.193 141.345 145.065 0.134
IBS-specific 
outpatient 8.045 7.633 8.479 5.411 5.161 5.673 <0.0005
All-cause ER 3.876 3.01 4.989 2.055 1.568 2.693 <0.0005
IBS-specific ER 0.391 0.161 0.948 0.527 0.256 1.085 0.497
All-cause 
prescription drugs 66.599 65.141 68.091 57.059 55.879 58.262 <0.0005
IBS-specific 
prescription drugs 9.543 8.999 10.119 7.83 7.409 8.275 <0.0005
IBS and depression group IBS only group
95% Confidence Interval 95% Confidence Interval
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Table 5. Comparison of healthcare costs among the two groups 
Type of cost P-value
Adjusted Mean Lower 95% CI Upper 95% CI Adjusted Mean Lower 95% CI Upper 95% CI
All-cause inpatient 
(in US $) 4,833 3,776 6,187 3,316 2,602 4,226 0.284
IBS-specific inpatient 
(in US $) 1,060 771 1,457 685 498 942 0.736
All-cause outpatient 
(in US $) 14,468 12,322 16,987 16,000 13,900 18,417 0.105
IBS-specific 
outpatient (in US $) 608 506 730 448 385 521 <0.0005
All-cause ER (in US 
$) 403 318 511 142 115 175 <0.0005
IBS-specific ER (in 
US $) 13 7 23 3 2 5 <0.0005
All-cause prescription 
drug (in US $)
4,738 4,104 5,469 4,168 3,674 4,728 0.011
IBS-specific 
prescription drug (in 
US $) 347 282 426 291 242 351 0.016
IBS and depression group IBS only group
95% Confidence Interval 95% Confidence Interval
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